Vol 94, No 7 (2023)
Research paper
Published online: 2023-02-17

open access

Page views 1187
Article views/downloads 479
Get Citation

Connect on Social Media

Connect on Social Media

Expression of heat shock proteins HSPA1A, HSPA1B and TP53 in vulval lichen planus and vulval lichen sclerosus

Adrianna Marzec1, Aleksandra Augusciak-Duma2, Dominika Kupny-Bujoczek1, Lukasz Witek1, Anita Olejek1, Iwona Gabriel1
Pubmed: 36929788
Ginekol Pol 2023;94(7):527-531.


Objectives: Heat shock proteins (HSPs) are proteins involved in protein folding and maturation. HSP expression is induced by heat shock or other stressors including cellular damage and hypoxia. The major groups, which are classified based on their molecular weight, include HSP27, HSP40, HSP60, HSP70, HSP90, and large HSP (HSP110 and glucose-regulated protein 170). The comparison of heat shock proteins and TP53 expression is yet not well studied in both vulval lichen sclerosus and lichen planus. Our aim was to assess the HSP and TP53 gene expression in women suffering from LS or LP and compare it within these groups and also healthy controls. Material and methods: The inclusion criteria were willingness to donate vulval biopsies, not currently or in the prior two weeks received any local nor systemic treatment for vulval disorder, age > 18 years old. The exclusion criteria were lack of consent, current vaginal infection confirmed with microbiological studies, current local or systemic treatment for vulval disease. 45 consecutive women were recruited into the study. All appropriate vulval samples were process by genetic analysis. Results: The mean expression (± SD) of HPSA1A for controls was 5.52 ± 3.18, for LS was 7.44 ± 2.16 and for LP was 7.89 ± 2.48. The mean expression (± SD) of HPSA1B for controls was 6.54 ± 3.41, for LS was 9.94 ± 6.88 and for LP was 9.43 ± 2.31. The mean expression (± SD) of TP53 for controls was 9.11 ± 1.14, for LS was 9.94 ± 1.27 and for LP was 10.41 ± 2.00. HSPA1A expression was 3,8 higher in women with lichen sclerosus than in control group. Conclusions: Heat shock protein-70 is more often expressed in LS than in healthy controls. HSP-70 not only supports tumor growth and metastasis, but on the other hand mat help to develop immune-driven treatment strategies.

Article available in PDF format

View PDF Download PDF file


  1. Aswad A, Liu T. Targeting heat shock protein 90 for anti-cancer drug development. Adv Cancer Res. 2021; 152: 179–204.
  2. Mayer MP, Bukau B. Hsp70 chaperones: cellular functions and molecular mechanism. Cell Mol Life Sci. 2005; 62(6): 670–684.
  3. Ellmalah MIY, Cordonnier M, Vautrot V, et al. Membrane-anchored heat-shock protein 70 (Hsp 70) in cancer. Cancer Lett. 2020; 469: 134–41.
  4. HSPA1A heat shock protein family A (Hsp70) member 1A [Homo sapiens (human)]. https://www.ncbi.nlm.nih.gov/gene/3303.
  5. HSPA1B heat shock protein family A (Hsp70) member 1B [Homo sapiens (human)]. https://www.ncbi.nlm.nih.gov/gene/3304.
  6. Park YH, Seo JiH, Park JH, et al. Hsp70 acetylation prevents caspase-dependent/independent apoptosis and autophagic cell death in cancer cells. Int J Oncol. 2017; 51(2): 573–578.
  7. Srinivasan SR, Cesa LC, Li X, et al. Heat Shock Protein 70 (Hsp70) Suppresses RIP1-Dependent Apoptotic and Necroptotic Cascades. Mol Cancer Res. 2018; 16(1): 58–68.
  8. Boudesco C, Cause S, Jego G, et al. Hsp70: A Cancer Target Inside and Outside the Cell. Methods Mol Biol. 2018; 1709: 371–396.
  9. Albakova Z, Armeev GA, Kanevskiy LM, et al. HSP70 Multi-Functionality in Cancer. Cells. 2020; 9(3).
  10. Kabakov AE, Gabai VL. HSP70s in Breast Cancer: Promoters of Tumorigenesis and Potential Targets/Tools for Therapy. Cells. 2021; 10(12).
  11. Lei Z, Xia X, He Q, et al. HSP70 promotes tumor progression by stabilizing Skp2 expression in gastric cancer cells. Mol Carcinog. 2021; 60(12): 826–839.
  12. Kasioumi P, Vrazeli P, Vezyraki P, et al. Hsp70 (HSP70A1A) downregulation enhances the metastatic ability of cancer cells. Int J Oncol. 2019; 54(3): 821–832.
  13. Bodzek P, Damasiewicz-Bodzek A, Janosz I, et al. Heat shock protein 27 (HSP27) in patients with ovarian cancer. Ginekol Pol. 2021; 92(12): 837–843.
  14. Boch K, Langan EA, Zillikens D, et al. Retrospective analysis of the clinical characteristics and patient-reported outcomes in vulval lichen planus: Results from a single-center study. J Dermatol. 2021; 48(12): 1913–1917.
  15. Pérez-López FR, Vieira-Baptista P. Lichen sclerosus in women: a review. Climacteric. 2017; 20(4): 339–347.
  16. Fistarol SK, Itin PH. Diagnosis and treatment of lichen sclerosus: an update. Am J Clin Dermatol. 2013; 14(1): 27–47.
  17. Simpson RC, Thomas KS, Leighton P, et al. Diagnostic criteria for erosive lichen planus affecting the vulva: an international electronic-Delphi consensus exercise. Br J Dermatol. 2013; 169(2): 337–343.
  18. Yeon J, Oakley A, Olsson A, et al. Vulval lichen sclerosus: An Australasian management consensus. Australas J Dermatol. 2021; 62(3): 292–299.
  19. Tavassol F, Starke OF, Völker B, et al. Heat-shock protein expression and topical treatment with tacrolimus in oral lichen planus: an immunohistochemical study. Int J Oral Maxillofac Surg. 2008; 37(1): 66–69.
  20. Bayramgürler D, Ozkara SK, Apaydin R, et al. Heat shock proteins 60 and 70 expression of cutaneous lichen planus: comparison with normal skin and psoriasis vulgaris. J Cutan Pathol. 2004; 31(9): 586–594.
  21. Carlson BC, Hofer MD, Ballek N, et al. Protein markers of malignant potential in penile and vulvar lichen sclerosus. J Urol. 2013; 190(2): 399–406.
  22. Liu YA, Ji JX, Almadani N, et al. Comparison of p53 immunohistochemical staining in differentiated vulvar intraepithelial neoplasia (dVIN) with that in inflammatory dermatoses and benign squamous lesions in the vulva. Histopathology. 2021; 78(3): 424–433.
  23. Bayramgürler D, Ozkara SK, Apaydin R, et al. Heat shock proteins 60 and 70 expression of cutaneous lichen planus: comparison with normal skin and psoriasis vulgaris. J Cutan Pathol. 2004; 31(9): 586–594.
  24. Sugerman PB, Savage NW, Xu LJ, et al. Heat shock protein expression in oral lichen planus. J Oral Pathol Med. 1995; 24(1): 1–8.
  25. Calderwood SK, Gong J. Heat Shock Proteins Promote Cancer: It's a Protection Racket. Trends Biochem Sci. 2016; 41(4): 311–323.
  26. Garg M, Kanojia D, Saini S, et al. Germ cell-specific heat shock protein 70-2 is expressed in cervical carcinoma and is involved in the growth, migration, and invasion of cervical cells. Cancer. 2010; 116(16): 3785–3796.
  27. Bar JK, Cierpikowski P, Lis-Nawara A, et al. Comparison of p53, HSP90, E-cadherin and HPV in oral lichen planus and oral squamous cell carcinoma. Acta Otorhinolaryngol Ital. 2021; 41(6): 514–522.
  28. Sadalla JC, Lourenço SV, Sotto MN, et al. Claudin and p53 expression in vulvar lichen sclerosus and squamous-cell carcinoma. J Clin Pathol. 2011; 64(10): 853–857.
  29. Raspollini MR, Asirelli G, Moncini D, et al. A comparative analysis of lichen sclerosus of the vulva and lichen sclerosus that evolves to vulvar squamous cell carcinoma. Am J Obstet Gynecol. 2007; 197(6): 592.e1–592.e5.
  30. Lv LH, Wan YL, Lin Y, et al. Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. J Biol Chem. 2012; 287(19): 15874–15885.
  31. Xie Y, Bai Ou, Zhang H, et al. Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70. J Cell Mol Med. 2010; 14(11): 2655–2666.